Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Satoris Launches 3 New Blood Tests To Help Researchers Identify Alzheimer's And Develop Drug Therapies
Satoris, Inc., a California-based molecular diagnostics company, announced today the launch of three research-use tests - two panels of plasma biomarkers shown to be significant in the neurodegenerative disease process, and a dementia discrimination panel. Specifically for use by Alzheimer"s researchers and by pharmaceutical companies developing new Alzheimer"s therapies, the panels are available now as a testing service.

Is Midline Or Transverse Incision Better For Abdominal Surgery?
An unusual study at the Department of Surgery at Heidelberg University Hospital examined for the first time whether the incision technique used in major abdominal surgery had an effect on the results. Neither physician nor patient knew what kind of incision had been made. The study of 200 patients showed that pain perception and the healing process were unrelated to the technique used to open the abdominal cavity. Complications were also just as frequent, except for wound infections, which were more frequent for transverse incisions, possibly due to circulatory problems. The surgeons in Heidelberg thus recommend that the surgeon make an individual, case-by-case decision on the incision technique.
News of the day
ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC). In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease. The compound also demonstrated encouraging activity against other CD56-expressing (CD56+) solid tumors. These clinical data are being presented at the 13th World Conference on Lung Cancer taking place in San Francisco, CA, from July 31 to Aug. 4, 2009.
Nutrition

Dose Measurement During Prostate Cancer Treatment

A new PTB measuring system offers the possibility of measuring the absorbed dose in the direct environment of the irradiated tumour During radiation therapy, the physicians try to keep the dose in the tumour as high as possible to destroy as many cancer cells as possible. To avoid the damaging of healthy tissue, it is becoming more and more important to check the exact amount of the dose. For this purpose, the Physikalisch-Technische Bundesanstalt (PTB) has developed a measuring system in the case of which the amino acid "alanine", whose radiation transport properties resemble those of human tissue, is used as indicator. When alanine is irradiated, free radicals are formed, whose concentration is measured with the aid of electron spin resonance (ESR). This allows the absorbed dose to be derived. First investigations on a phantom and also on patients have shown that the method is well functioning. Physikalisch-Technische Bundesanstalt (PTB)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009